FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898197951> ?p ?o ?g. }

• W2898197951 endingPage "e12965" @default.
• W2898197951 startingPage "e12965" @default.
• W2898197951 abstract "Abstract This study aimed to analyze the relationship between pathologic complete response (pCR) and changes in background parenchymal enhancement (BPE) levels in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and who received neoadjuvant chemotherapy (NAC). The pre- and post-NAC magnetic resonance imaging results of 51 patients with confirmed unilateral HER2-positive breast cancer were retrospectively analyzed by 2 experienced radiologists. Pre- and post-NAC of contralateral BPE levels were classified into 4 categories (1 = minimal, 2 = mild, 3 = moderate, and 4 = marked). The 4 categories of BPE were defined by the visually estimated enhancement of fibroglandular tissue of the breast. Changes in BPE before and after NAC were compared between the premenopausal and postmenopausal groups and between the pCR and non-pCR groups. The associations between BPE and pCR and between BPE and tumor size were analyzed before and after NAC. Twenty-three patients achieved pCR, and 28 patients achieved non-pCR. Premenopausal patients had significantly higher baseline BPE levels than postmenopausal women ( P = .023). The post-NAC BPE levels of premenopausal patients significantly decreased relative to those of postmenopausal patients ( P = .027). The baseline BPE levels of the pCR group were not significantly different from those of the non-pCR group ( P = .892). However, the decrease in BPE levels in the pCR group was more drastic than that in the non-pCR group ( P < .001). Decreased BPE levels were directly associated with pCR and tumor size reduction ( P < .05). Women with hormone receptor (HR)-negative tumors were more likely to exhibit pCR than those with HR-positive tumors ( P = .007). Decreased BPE of patients with HER2-positive breast cancer may serve as an indicator of NAC effectiveness. Furthermore, women with HR-negative tumors were more likely to exhibit pCR than women with HR-positive tumors." @default.
• W2898197951 created "2018-11-02" @default.
• W2898197951 creator A5011487190 @default.
• W2898197951 creator A5011676944 @default.
• W2898197951 creator A5018480888 @default.
• W2898197951 creator A5021541475 @default.
• W2898197951 creator A5022531106 @default.
• W2898197951 creator A5034272890 @default.
• W2898197951 creator A5038077278 @default.
• W2898197951 creator A5063863422 @default.
• W2898197951 creator A5067027007 @default.
• W2898197951 creator A5070318923 @default.
• W2898197951 creator A5074302858 @default.
• W2898197951 date "2018-10-01" @default.
• W2898197951 modified "2023-10-06" @default.
• W2898197951 title "Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy" @default.
• W2898197951 cites W1206024630 @default.
• W2898197951 cites W1930049574 @default.
• W2898197951 cites W1948233554 @default.
• W2898197951 cites W1977988499 @default.
• W2898197951 cites W1994110859 @default.
• W2898197951 cites W1996778928 @default.
• W2898197951 cites W1997872096 @default.
• W2898197951 cites W1999898292 @default.
• W2898197951 cites W2020361707 @default.
• W2898197951 cites W2020508063 @default.
• W2898197951 cites W2038833688 @default.
• W2898197951 cites W2042512477 @default.
• W2898197951 cites W2045684235 @default.
• W2898197951 cites W2048002869 @default.
• W2898197951 cites W2072383130 @default.
• W2898197951 cites W2075894019 @default.
• W2898197951 cites W2087732511 @default.
• W2898197951 cites W2095861620 @default.
• W2898197951 cites W2102519580 @default.
• W2898197951 cites W2130900820 @default.
• W2898197951 cites W2131803941 @default.
• W2898197951 cites W2165114807 @default.
• W2898197951 cites W2201588237 @default.
• W2898197951 cites W2323948157 @default.
• W2898197951 cites W2336817568 @default.
• W2898197951 cites W2607011818 @default.
• W2898197951 cites W2733216021 @default.
• W2898197951 cites W2742601397 @default.
• W2898197951 cites W2766301980 @default.
• W2898197951 cites W2805679458 @default.
• W2898197951 doi "https://doi.org/10.1097/md.0000000000012965" @default.
• W2898197951 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6221660" @default.
• W2898197951 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30412117" @default.
• W2898197951 hasPublicationYear "2018" @default.
• W2898197951 type Work @default.
• W2898197951 sameAs 2898197951 @default.
• W2898197951 citedByCount "12" @default.
• W2898197951 countsByYear W28981979512020 @default.
• W2898197951 countsByYear W28981979512021 @default.
• W2898197951 countsByYear W28981979512022 @default.
• W2898197951 countsByYear W28981979512023 @default.
• W2898197951 crossrefType "journal-article" @default.
• W2898197951 hasAuthorship W2898197951A5011487190 @default.
• W2898197951 hasAuthorship W2898197951A5011676944 @default.
• W2898197951 hasAuthorship W2898197951A5018480888 @default.
• W2898197951 hasAuthorship W2898197951A5021541475 @default.
• W2898197951 hasAuthorship W2898197951A5022531106 @default.
• W2898197951 hasAuthorship W2898197951A5034272890 @default.
• W2898197951 hasAuthorship W2898197951A5038077278 @default.
• W2898197951 hasAuthorship W2898197951A5063863422 @default.
• W2898197951 hasAuthorship W2898197951A5067027007 @default.
• W2898197951 hasAuthorship W2898197951A5070318923 @default.
• W2898197951 hasAuthorship W2898197951A5074302858 @default.
• W2898197951 hasBestOaLocation W28981979511 @default.
• W2898197951 hasConcept C121608353 @default.
• W2898197951 hasConcept C126322002 @default.
• W2898197951 hasConcept C126838900 @default.
• W2898197951 hasConcept C126894567 @default.
• W2898197951 hasConcept C143409427 @default.
• W2898197951 hasConcept C143998085 @default.
• W2898197951 hasConcept C23589133 @default.
• W2898197951 hasConcept C2776694085 @default.
• W2898197951 hasConcept C530470458 @default.
• W2898197951 hasConcept C71315377 @default.
• W2898197951 hasConcept C71924100 @default.
• W2898197951 hasConcept C90924648 @default.
• W2898197951 hasConceptScore W2898197951C121608353 @default.
• W2898197951 hasConceptScore W2898197951C126322002 @default.
• W2898197951 hasConceptScore W2898197951C126838900 @default.
• W2898197951 hasConceptScore W2898197951C126894567 @default.
• W2898197951 hasConceptScore W2898197951C143409427 @default.
• W2898197951 hasConceptScore W2898197951C143998085 @default.
• W2898197951 hasConceptScore W2898197951C23589133 @default.
• W2898197951 hasConceptScore W2898197951C2776694085 @default.
• W2898197951 hasConceptScore W2898197951C530470458 @default.
• W2898197951 hasConceptScore W2898197951C71315377 @default.
• W2898197951 hasConceptScore W2898197951C71924100 @default.
• W2898197951 hasConceptScore W2898197951C90924648 @default.
• W2898197951 hasIssue "43" @default.
• W2898197951 hasLocation W28981979511 @default.
• W2898197951 hasLocation W28981979512 @default.
• W2898197951 hasLocation W28981979513 @default.

• next